world
La terapia triple permite que cuatro de cada diez pacientes con cáncer de próstata metastásico sigan vivos a los ocho años
20minutos
October 24, 2026
via 20minutosYou're reading one story from Newsaly
Newsaly brings together 60,000+ newspaper articles, 30,000+ podcasts and 10,000+ magazine articles from around the world.
A World Of News, One Window.
Explore Today's News
El ensayo internacional Peace-1 demuestra que añadir abiraterona al tratamiento habitual reduce hasta un 32% el riesgo de muerte y aumenta la supervivencia media de 4,4 a 6,2 años.
Read the full story
Explore More On Newsaly
Voices (0)
Share a 15-second voice reaction. Voices automatically disappear after 10 days.
Sign in to record a voice on this article.
Be the first to share a voice on this article.